Universal Biosensors, Inc. (ASX:UBI)

Market Cap	4.17M -90.0%
Revenue (ttm)	5.95M -16.5%
Net Income	-17.46M
EPS	-0.06
Shares Out	298.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	132,045
Average Volume	615,066
Open	0.0140
Previous Close	0.0140
Day's Range	0.0130 - 0.0140
52-Week Range	0.0120 - 0.1600
Beta	0.31
RSI	30.96
Earnings Date	Feb 25, 2026

About Universal Biosensors

Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of the anticoagulant therapy warfarin; and Sentia wine testing products, such as free SO₂, malic acid, glucose, fructose, total acid, and titratable acid...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2001
• Employees: 76
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: UBI

Financial Performance

In 2024, Universal Biosensors's revenue was 6.28 million, a decrease of -5.28% compared to the previous year's 6.63 million. Losses were -14.24 million, 111.2% more than in 2023.